Compare MGRC & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGRC | IDYA |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.9B |
| IPO Year | 1995 | 2019 |
| Metric | MGRC | IDYA |
|---|---|---|
| Price | $111.59 | $28.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 16 |
| Target Price | ★ $141.50 | $52.86 |
| AVG Volume (30 Days) | 261.9K | ★ 1.6M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ 1.10 | N/A |
| Revenue | ★ $944,235,000.00 | $218,710,000.00 |
| Revenue This Year | $4.69 | N/A |
| Revenue Next Year | $4.81 | $201.05 |
| P/E Ratio | $99.12 | ★ N/A |
| Revenue Growth | 3.65 | ★ 3024.43 |
| 52 Week Low | $94.99 | $16.82 |
| 52 Week High | $128.41 | $39.28 |
| Indicator | MGRC | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 47.41 | 39.72 |
| Support Level | $105.02 | $26.05 |
| Resistance Level | $117.98 | $34.76 |
| Average True Range (ATR) | 4.39 | 1.38 |
| MACD | -0.56 | -0.33 |
| Stochastic Oscillator | 42.32 | 13.64 |
McGrath RentCorp is a diversified business-to-business rental company with three rental divisions: relocatable modular buildings, portable storage containers, and electronic test equipment. It comprises four reportable business segments, namely the Modular Building segment (Mobile Modular), which generates maximum revenue; the Portable Storage segment (Portable Storage); the Electronic Test Equipment segment (TRS-RenTelco); and its classroom manufacturing business (Enviroplex), which sells modular buildings used as classrooms in California. The company generates its revenues mainly from the rental of its equipment under operating leases, with sales of equipment occurring in the normal course of business.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.